


Tchaikapharma High Quality Medicines Inc.
Consolidated Statement of financial position
as of 30 September 2024


	30.09.2024	31.12.2023
	BGN'000	BGN'000
Non-current assets		
Property, plant and equipment	34,465	33,083
Intangible Assets and Goodwill	3,567	3,560
Trade receivables	4,978	4,978
Non-current assets	43,010	41,621
Inventories	15,298	14,303
Trade and other receivables	66,749	66,490
Current tax assets	-	12
Cash and cash equivalents	174	73
Current Assets	82,221	80,878
Assets	125,231	122,499
Issued capital	91,800	84,500
Statutory reserve	13,147	12,800
Retained earnings	4,398	7,701
Equity	109,345	105,001
<i>Equity Attributable to owners of the parent company</i>	<i>109,345</i>	<i>105,001</i>
<i>Non-controlling interest in equity</i>	<i>-</i>	<i>-</i>
Long term borrowings	659	879
Deferred tax liabilities	1,113	1,113
Non-current provisions for employee benefits	173	197
Non-current liabilities	1,945	2,632
Trade and other payables	3,456	4,768
Short term borrowings	10,065	10,298
Current tax liabilities	420	243
Current liabilities	13,941	15,309
Liabilities	15,886	17,498
Equity and liabilities	125,231	122,499

Date of preparation: 19.11.2024

Executive director:


Biser Georgiev

Prepared by:


Petya Moneva

Tchaikapharma High Quality Medicines Inc.
Consolidated statement of comprehensive income
as 30 September 2024


	30.09.2024	30.09.2023
	BGN'000	BGN'000
Revenue	40,414	39,076
Other income	182	64
Total income	40,596	39,140
Carrying amount of goods sold	(1,945)	(775)
Changes in inventories of finished products and work in progress	318	(509)
Materials and services	(24,712)	(24,922)
Personnel expenses	(6,664)	(4,773)
Depreciation / amortisation expenses	(1,877)	(2,198)
Other expenses	(434)	(775)
Finance income	40	46
Finance costs	(550)	(480)
Total expenses	(35,832)	(34,386)
Profit Loss before tax	4,764	4,754
Current tax expense income	(420)	(350)
Profit Loss	4,344	4,404
<i>Profit Loss attributable to owners of the parent company</i>	<i>4,344</i>	<i>4,404</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Other comprehensive income	4,344	4,404
<i>Profit Loss attributable to owners of the parent company</i>		
<i>Profit Loss attributable to non-controlling interests</i>		
Comprehensive income	4,344	4,404
<i>Profit Loss attributable to owners of the parent company</i>	<i>4,344</i>	<i>4,404</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Earnings per share / in BGN per 1 share /	0.05	0.05

Date of preparation: 19.11.2024

Executive director:


Biser Georgiev

Prepared by:


Petya Moneva

Tchaikapharma High Quality Medicines Inc.
Consolidated Cash flow statement
as of 30 September 2024

	30.09.2024	30.09.2023
	BGN'000	BGN'000
Cash flows from operating activities		
Receipts from sales of goods and rendering of services	30,227	24,559
Payments to suppliers for goods and services	(15,642)	(13,077)
Payments to and on behalf of employees	(6,832)	(4,462)
Income taxes paid classified as operating activities	(408)	(323)
Other cash payments from operating activities	(4,730)	(4,379)
Cash flows from used in operating activities	2,615	2,318
 Cash flows from investing activities		
Purchase of other longterm assets classified as investing activities	(1,687)	(1,605)
Cash flows from used in investing activities	(1,687)	(1,605)
 Cash flows from financial activities		
Dividends paid classified as financing activities	438	357
Proceeds from borrowings classified as financing activities	(446)	(360)
Repayments of borrowings classified as financing activities	(428)	(375)
Payments of lease liabilities classified as financing activities	(391)	(391)
Cash flows from used in financial activities	(827)	(769)
 Increase/Decrease in cash and cash equivalents	101	(56)
Cash and cash equivalents	73	142
Cash and cash equivalents	174	86

Date of preparation: 19.11.2024

Executive director:


Biser Georgiev

Prepared by:


Petya Moneva

Tchaikapharma High Quality Medicines Inc.
Consolidated statement on changes in equity
as of 30 September 2024


	Issued capital <i>BGN'000</i>	Property plant and equipme nt revaluati on surplus <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings <i>BGN'000</i>	Equity abstract <i>BGN'000</i>	Equity Attributab le to owners of the parent company <i>BGN'000</i>	Non- controllin g interest in equity <i>BGN'000</i>
Balance as of 01.01.2023	84,500	4,351	8,147	4,587	101,585	101,585	-
Profit Loss	-	-	-	3,398	3,398	3,398	-
Other comprehensive income	-	18	-	-	-	-	-
Comprehensive income	-	18	-	3,398	3,416	3,416	-
Increase/Decrease through appropriation of retained earnings	-	-	284	(284)	-	-	-
Total income expense	-	-	284	(284)	-	-	-
Balance as of 31.12.2023	84,500	4,369	8,431	7,701	105,001	105,001	-
Balance as of 01.01.2024	84,500	4,369	8,431	7,701	105,001	105,001	-
Profit Loss	-	-	-	4,344	4,344	4,344	-
Other comprehensive income	-	-	-	-	-	-	-
Comprehensive income	-	-	-	4,344	4,344	4,344	-
Increase/Decrease through appropriation of retained earnings	7,300	-	347	(7,647)	-	-	-
Total income expense	7,300	-	347	(7,647)	-	-	-
Balance as of 30.09.2024	91,800	4,369	8,778	4,398	109,345	109,345	-

Date of preparation: 19.11.2024

Executive director:


Biser Georgiev

Prepared by:


Petya Moneva